OS for relapsed and primary refractory (R/R) patients with MTCL and MNKCL stratified by histological subtype comparing second-line treatment with CC vs “novel” SA. Kaplan-Meier curves show OS estimates since the start of second-line treatment for patients with PTCL-NOS (A), AITL (B), ENKTCL (C), ALK⁺ ALCL (D), and ALK^– ALCL (E). Results depicted apply to the global data set of 763 patients for whom information on start dates of second-line treatment was available. P values calculated by log-rank test.